G1 Therapeutics Company Insiders
GTHX Stock | USD 4.11 0.06 1.44% |
G1 Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding G1 Therapeutics suggests that vertually all insiders are panicking. G1 Therapeutics employs about 100 people. The company is managed by 30 executives with a total tenure of roughly 141 years, averaging almost 4.0 years of service per executive, having 3.33 employees per reported executive.
Mark Velleca CEO President CEO, Director |
Seth Rudnick Chairman Chairman of the Board |
G1 Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-03-18 | John W V Umstead | Disposed 6547 @ 3.02 | View | ||
2024-02-12 | Rajesh Malik | Disposed 28600 @ 4.62 | View | ||
2024-01-04 | Terry L Murdock | Disposed 721 @ 2.94 | View | ||
2024-01-03 | Rajesh Malik | Disposed 3019 @ 3.12 | View | ||
2024-01-02 | John E (Jack) Jr. Bailey | Disposed 32983 @ 3.27 | View | ||
2023-12-11 | Rajesh Malik | Disposed 33839 @ 3.41 | View | ||
2023-07-05 | Terry L Murdock | Disposed 1361 @ 2.45 | View |
Monitoring G1 Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
GTHX |
G1 Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with G1 Therapeutics' future performance. Based on our forecasts, it is anticipated that GTHX will maintain a workforce of slightly above 100 employees by May 2024.G1 Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1596) % which means that it has lost $0.1596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9213) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, G1 Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 121 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.9 M in 2024.Common Stock Shares Outstanding is likely to drop to about 33.7 M in 2024. Net Loss is likely to rise to about (126.2 M) in 2024
G1 Therapeutics Workforce Comparison
G1 Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 5,374. G1 Therapeutics claims roughly 100.0 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.58) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.6) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.6. G1 Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific G1 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on G1 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, G1 Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.9 | 18 | 20 | 1,159,630 | 123,133 |
2023-12-01 | 0.5 | 2 | 4 | 33,839 | 67,678 |
2023-09-01 | 0.25 | 2 | 8 | 60,000 | 125,796 |
2023-06-01 | 20.0 | 20 | 1 | 775,000 | 0.00 |
2023-03-01 | 0.9412 | 16 | 17 | 729,600 | 71,168 |
2022-12-01 | 0.5 | 2 | 4 | 29,000 | 54,000 |
2022-09-01 | 0.5 | 4 | 8 | 178,000 | 237,296 |
2022-03-01 | 1.8 | 18 | 10 | 634,833 | 68,683 |
2021-12-01 | 1.0 | 1 | 1 | 40,000 | 40,000 |
2021-09-01 | 0.2857 | 2 | 7 | 310,000 | 60,000 |
2021-06-01 | 0.76 | 19 | 25 | 257,365 | 260,000 |
2021-03-01 | 1.0 | 25 | 25 | 1,043,473 | 222,180 |
2020-12-01 | 0.3333 | 5 | 15 | 77,000 | 131,016 |
2020-03-01 | 2.5 | 15 | 6 | 929,500 | 19,500 |
2019-09-01 | 2.0 | 2 | 1 | 302,000 | 2,000 |
2019-03-01 | 2.6 | 13 | 5 | 657,818 | 58,333 |
2018-12-01 | 0.5854 | 24 | 41 | 92,709 | 157,428 |
2018-09-01 | 0.3721 | 16 | 43 | 302,616 | 123,232 |
2018-06-01 | 0.5 | 18 | 36 | 312,778 | 909,856 |
2018-03-01 | 0.8095 | 17 | 21 | 265,278 | 76,356 |
2017-12-01 | 0.7143 | 5 | 7 | 509,490 | 747,932 |
2017-06-01 | 0.3393 | 19 | 56 | 17,535,716 | 54,626,928 |
G1 Therapeutics Notable Stakeholders
A G1 Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as G1 Therapeutics often face trade-offs trying to please all of them. G1 Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting G1 Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mark Velleca | President CEO, Director | Profile | |
John Bailey | President CEO | Profile | |
Seth Rudnick | Chairman of the Board | Profile | |
Barclay Phillips | CFO and Senior Vice President - Corporate Development | Profile | |
Jennifer Moses | Vice President - Finance and Administration | Profile | |
Terry Murdock | Senior Vice President - Development Operations | Profile | |
Andrew Witty | Director | Profile | |
Glenn Muir | Independent Director | Profile | |
Garry Nicholson | Independent Director | Profile | |
Tyrell Rivers | Independent Director | Profile | |
Fredric Eshelman | Independent Director | Profile | |
Willie Deese | Independent Director | Profile | |
Cynthia Schwalm | Independent Director | Profile | |
Christy Shaffer | Independent Director | Profile | |
Jay Strum | Chief Scientific Officer | Profile | |
Alexander MS | VP Operations | Profile | |
ChB MB | Chief RD | Profile | |
John Demaree | Chief Commercial Officer | Profile | |
Evan MBA | Vice Marketing | Profile | |
Monica Thomas | General Officer | Profile | |
James Hanson | General Counsel | Profile | |
Andrew Perry | Chief Officer | Profile | |
Jeff Macdonald | Head of Investor Relations/Public Relations | Profile | |
Jennifer CPA | Chief Officer | Profile | |
Gregory Mossinghoff | Chief Business Officer, Secretary | Profile | |
Robert Uhl | IR Contact Officer | Profile | |
John V | Chief Officer | Profile | |
Rajesh Malik | Chief Medical Officer | Profile | |
William Roberts | Vice Communications | Profile | |
Mark Avagliano | Chief Officer | Profile |
About G1 Therapeutics Management Performance
The success or failure of an entity such as G1 Therapeutics often depends on how effective the management is. G1 Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GTHX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GTHX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.39) | (0.41) | |
Return On Capital Employed | (0.43) | (0.45) | |
Return On Assets | (0.39) | (0.41) | |
Return On Equity | (1.36) | (1.29) |
The data published in G1 Therapeutics' official financial statements usually reflect G1 Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of G1 Therapeutics. For example, before you start analyzing numbers published by GTHX accountants, it's critical to develop an understanding of what G1 Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of G1 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, G1 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in G1 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of G1 Therapeutics. Please utilize our Beneish M Score to check the likelihood of G1 Therapeutics' management manipulating its earnings.
G1 Therapeutics Workforce Analysis
Traditionally, organizations such as G1 Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare G1 Therapeutics within its industry.G1 Therapeutics Manpower Efficiency
Return on G1 Therapeutics Manpower
Revenue Per Employee | 825.1K | |
Revenue Per Executive | 2.8M | |
Net Loss Per Employee | 479.7K | |
Net Loss Per Executive | 1.6M | |
Working Capital Per Employee | 852.3K | |
Working Capital Per Executive | 2.8M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
CEOs Directory Screen CEOs from public companies around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.